
WhiteLab Genomics provides an AI-driven platform that speeds discovery and design of genomic therapies, reducing time and experimental workload. It combines graph knowledge technology, machine learning, and advanced computational biology to perform in-silico design and optimization of vectors, payloads, genotoxicity assessment, and experimental protocols. The platform supports modalities including AAV, lentiviral, and nanoparticle delivery and is used by biopharmaceutical companies and research institutions. WhiteLab's tools integrate into genomic R&D workflows to de-risk early development and accelerate candidate selection for downstream preclinical testing.

WhiteLab Genomics provides an AI-driven platform that speeds discovery and design of genomic therapies, reducing time and experimental workload. It combines graph knowledge technology, machine learning, and advanced computational biology to perform in-silico design and optimization of vectors, payloads, genotoxicity assessment, and experimental protocols. The platform supports modalities including AAV, lentiviral, and nanoparticle delivery and is used by biopharmaceutical companies and research institutions. WhiteLab's tools integrate into genomic R&D workflows to de-risk early development and accelerate candidate selection for downstream preclinical testing.
What they do: AI-driven platform (ALFRED AI) for design and optimization of genomic medicines (AAV, lentiviral, non-viral vectors, payloads, bioproduction)
Founded: 2019
Headquarters / presence: Paris, Boston, Montréal
Funding: $10M seed (Sep 12, 2022); pre-seed tied to Y Combinator (Mar 2022)
Investors / partners: Debiopharm Group, Omnes Capital, Y Combinator
Accelerating and de-risking genomic medicine R&D (gene and cell therapy development).
2019
Biotechnology
Pre-seed round associated with Y Combinator
10000000
Seed round announced Sep 12, 2022
“Debiopharm Group and Omnes Capital are lead investors; Y Combinator participated in earlier round”
| Company |
|---|
As our Scientist (reporting to the Head of Translational Science), you’ll lead experiments on peptide/small-molecule–target interactions that power and validate our AI, working hand-in-hand with Protein & Vector Engineering team and external partners to advance gene and cell therapy delivery.
Here’s How You’ll Make an Impact
Scan emerging trends in biophysics, peptide therapeutics, and molecular engineering and introduce methods that raise speed, quality, or throughput.
Standardize best practices, templates, and SOPs to continuously improve experimental workflows.We’re Eager to Meet You If…
You hold a PhD or Engineering degree in Biochemistry, Biophysics, Chemical Biology, Molecular Pharmacology, or a related field, with 3–5+ years in therapeutic discovery or translational research.
You have proven expertise in biophysical interaction analysis (e.g., SPR, BLI, or related kinetic techniques).
You bring hands-on experience in peptide and protein modalities: peptide synthesis/modification, nanobody/protein engineering, and/or small-molecule binding evaluation.
You have assessed efficacy and pharmacology for peptides and small molecules via in vitro and in vivo studies, and can interpret the resulting data with rigor.
You’ve run high-throughput screening using display technologies (phage display, mRNA display, or similar platforms).
You manage external collaborations effectively (CROs, academic/industry partners) to deliver non-clinical studies on time and to spec.
You communicate clearly and credibly, with strong written/oral skills, a solid publication record, and the ability to present complex findings to diverse stakeholders.
You’re a creative problem-solver, comfortable tackling complex scientific challenges and adapting quickly to shifting research priorities.You will first have a video interview with the Head of People and Culture, followed by a second video interview with the Head of Early Pre-Clinical Research and last one with our CSO. Subsequently, you will be invited for an on-site, face-to-face interview to meet the rest of the team and complete a PI test and reference check.